Compare Albertsons Companies Inc (ACI) vs Quest Diagnostics Inc (DGX) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Albertsons Companies Inc vs Quest Diagnostics Inc — how do they compare? Albertsons Companies Inc trades at $14.24 (market cap $6.93B), while Quest Diagnostics Inc trades at $207.95 (market cap $23.51B). The key difference: Quest Diagnostics Inc is far larger — about 3.4× Albertsons Companies Inc's market cap, and Albertsons Companies Inc pays the higher dividend (4.81%). Which is the better fit depends on your goals.
| ACI | DGX | |
|---|---|---|
Market Cap | $6.93B | $23.51B |
Sector | Consumer Staples | Health |
52-Week High | $22.33 | $216.02 |
52-Week Low | $13.45 | $166.42 |
Enterprise Value | $22.02B | $29.52B |
Dividend Yield | 4.81% | 1.62% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Albertsons Companies (ACI) trades at $14.14, showing minimal daily movement with a 0.07% gain. The stock demonstrates strong earnings momentum with three consecutive quarterly beats, though profitability margins remain thin at 0.26% net income margin. Analyst consensus is bullish with a $18.75 price target representing 33% upside potential. Recent developments include AI-powered search enhancements and retail media partnerships driving innovation.
ACI presents a compelling value opportunity with attractive valuation metrics (P/S: 0.09, EV/EBITDA: 6.49) and consistent revenue growth, though investors face risks from declining profit margins, increasing debt levels, and competitive grocery market pressures. The technical picture remains bearish despite fundamental strengths.
Quest Diagnostics (DGX) trades at $212.38, down 1.55% today but remains near its 52-week high. The stock shows strong fundamental performance with three consecutive quarterly earnings beats and revenue growth to $11.04 billion in 2025. Technical indicators suggest a bullish trend with support at $212 and resistance at $216. Recent positive developments include New York State approval for the Haystack MRD cancer test, expanding market reach.
DGX presents a balanced investment case with solid fundamentals and analyst support, though valuation appears full. The consensus price target of $222.80 offers modest upside. Key risks include healthcare reimbursement pressures and elevated debt levels. Earnings growth and diagnostic service expansion remain primary catalysts for continued performance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Albertsons Companies Inc
Albertsons is the second-largest traditional grocer in America, operating 2,276 stores under 24 banners in 34 states (as of the end of fiscal 2021). Around 75% of stores have pharmacies, while nearly 20% also sell fuel. Albertsons has a significant private-label operation, accounting for around 20% of sales (excluding fuel). While its own brand assortment is mainly manufactured by third parties, Albertsons operates 20 food production plants (as of the end of fiscal 2021). Albertsons is a top-two grocer in two thirds of its major markets (as of early 2022, according to company data), and virtually all of its sales come from the United States.
Read more on ACI →About Quest Diagnostics Inc
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
Read more on DGX →
